Clinical Trials
2 trialsNCT00654420 2018-08-08
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00729742 2016-04-04
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Merck Sharp & Dohme LLC
Phase 1 Completed